MiR-200c sensitizes Olaparib-resistant ovarian cancer cells by targeting Neuropilin 1

BACKGROUND: Ovarian cancer (OC) is the most lethal gynecological malignancy and the second leading cause of cancer-related death in women. Treatment with PARP inhibitors (PARPi), such as Olaparib, has been recently introduced for OC patients, but resistance may occur and underlying mechanisms are st...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Exp Clin Cancer Res
Hauptverfasser: Vescarelli, Enrica, Gerini, Giulia, Megiorni, Francesca, Anastasiadou, Eleni, Pontecorvi, Paola, Solito, Luciana, De Vitis, Claudia, Camero, Simona, Marchetti, Claudia, Mancini, Rita, Benedetti Panici, Pierluigi, Dominici, Carlo, Romano, Ferdinando, Angeloni, Antonio, Marchese, Cinzia, Ceccarelli, Simona
Format: Artigo
Sprache:Inglês
Veröffentlicht: BioMed Central 2020
Schlagworte:
Research
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6939329/
https://ncbi.nlm.nih.gov/pubmed/31898520
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-019-1490-7
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge